Impaired hepatitis B vaccine responses during chronic hepatitis C infection: Involvement of the PD-1 pathway in regulating CD4+ T cell responses
Autor: | Lei Ni, Jonathan P. Moorman, Xiao Y. Wu, Chun L. Zhang, Cheng J. Ma, Thomas Borthwick, Tareq M. Islam, Ying Zhang, Zhi Q. Yao, Penny Thayer |
---|---|
Rok vydání: | 2011 |
Předmět: |
Adult
CD4-Positive T-Lymphocytes Male HBsAg Hepatitis B vaccine T cell Programmed Cell Death 1 Receptor Biology Lymphocyte Activation medicine.disease_cause Article Cohort Studies Antigens CD medicine Humans Hepatitis B Vaccines Aged Cell Proliferation Hepatitis B virus Hepatitis B Surface Antigens General Veterinary General Immunology and Microbiology Gene Expression Profiling Public Health Environmental and Occupational Health virus diseases Hepatitis C Hepatitis C Chronic Middle Aged Hepatitis B medicine.disease Virology digestive system diseases Vaccination Infectious Diseases medicine.anatomical_structure Immunology Molecular Medicine Female Apoptosis Regulatory Proteins Cell activation |
Zdroj: | Vaccine. 29:3169-3176 |
ISSN: | 0264-410X |
DOI: | 10.1016/j.vaccine.2011.02.052 |
Popis: | Vaccination for hepatitis B virus (HBV) in the setting of hepatitis C virus (HCV) infection is recommended, but responses to vaccination are blunted when compared to uninfected populations. The mechanism for this failure of immune response in HCV-infected subjects remains unknown but is thought to be a result of lymphocyte dysfunction during chronic viral infection. We have recently demonstrated that PD-1, a novel negative immunomodulator for T cell receptor (TCR) signaling, is involved in T and B lymphocyte dysregulation during chronic HCV infection. In this report, we further investigated the role of the PD-1 pathway in regulation of CD4(+) T cell responses to HBV vaccination in HCV-infected individuals. In a prospective HCV infected cohort, a poor response rate to HBV vaccination as assayed by seroconversion was observed in HCV-infected subjects (53%), while a high response rate was observed in healthy or spontaneously HCV-resolved individuals (94%). CD4(+) T cell responses to ex vivo stimulations of anti-CD3/CD28 antibodies or hepatitis B surface antigen (HBsAg) were found to be lower in HBV vaccine non-responders compared to those responders in HCV-infected individuals who had received a series of HBV immunizations. PD-1 expression on CD4(+) T cells was detected at relatively higher levels in these HBV vaccine non-responders than those who responded, and this was inversely associated with the cell activation status. Importantly, blocking the PD-1 pathway improved T cell activation and proliferation in response to ex vivo HBsAg or anti-CD3/CD28 stimulation in HBV vaccine non-responders. These results suggest that PD-1 signaling may be involved in impairing CD4(+) T cell responses to HBV vaccination in subjects with HCV infection, and raise the possibility that blocking this negative signaling pathway might improve success rates of immunization in the setting of chronic viral infection. |
Databáze: | OpenAIRE |
Externí odkaz: |